Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Rapport Therapeutics, Inc.

NASDAQ: RAPP · Life Sciences · 15 alerts · CIK 2012593

Share price
$24.82Close, Nov 16
Market cap
$1.47B
Shares outstanding
59.28MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Rapport Therapeutics, Inc. filings on SEC EDGAR ↗

7:31 AM ET 10-Q
Financial Results

Rapport Therapeutics Q3 2026 Results: Net Loss of $40.2M, Loss Widens

Rapport Therapeutics is a clinical-stage biotechnology company that has incurred significant financial losses since inception and expects to continue doing so. As of November 2, 2026, the company had 59,279,630 shares of common stock outstanding and is focused on developing its lead product candidate, RAP-219, for neurological disorders.

Key figure
Net loss $40.2M
7:13 AM ET 8-K
Financial Results

Rapport Therapeutics Financial Results

Rapport Therapeutics reported third quarter 2026 financial results and highlighted positive Phase 2 topline results for RAP-219 in bipolar mania. The company is well-capitalized with $815.4 million in cash following a recent financing, providing a projected runway through the end of 2029.

Term
Q3 2026

“Our positive Phase 2 results in bipolar mania are transformational for Rapport, accelerating our path to becoming an industry-leading precision neuroscience company. RAP-219 now has clinical proof-of-concept in two indications across neurology and psychiatry, giving us the opportunity to serve patients in two multibillion-dollar markets.”

Abraham N. Ceesay, chief executive officer of Rapport

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.